Literature DB >> 12444382

Diversity of clinical symptoms in A3243G mitochondrial DNA mutation (MELAS syndrome mutation).

Maciej Pronicki1, Jolanta Sykut-Cegielska, Hanna Mierzewska, Katarzyna Tońska, Elzbieta Karczmarewicz, Katarzyna Iwanicka, Ewa Bartnik, Ewa Pronicka.   

Abstract

BACKGROUND: MELAS (mitochondrial myopathy, lactic acidosis and stroke-like episodes) is one of the most common mitochondrial encephalomyopathies. MATERIAL/
METHODS: We present four children with A3243G MELAS mtDNA mutation and give a summary of clinical MELAS symptoms reported in the literature. Serum lactate elevation, mosaic pattern of COX deficit and decreased activity of complex I and IV in the muscle biopsy were found in all cases. RRFs were recognized in three out of four.
RESULTS: The main features seen in all our patients were poor growth and fatigability with muscle weakness. All presented epileptic jerks of various character, some deformation features (recurrent pretibial and peritarsal edema, large swollen-looking hands and feet, hypertelorism and protruding ears) and some cutaneous lesions (atopic dermatitis, local melanoderma, asymmetric vascular dilatation). Stroke-like episodes, multihormonal hypopituitarism, sensorineural hypoacusis, pigmentary retinal degeneration, intracranial calcification, heart involvement, recurrent vomiting or abdominal pain were seen only in individual cases. The homonymous hemianopia frequently reported in the literature was not a feature of our patients. One of them suffered from nonspecific sialoadenitis never mentioned in the literature.
CONCLUSIONS: Morphological, enzymatic and molecular investigations of a muscle biopsy sample should be undertaken to improve early MELAS detection in patients with any multiorgan disease associated with serum lactate elevation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444382

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  9 in total

1.  Maternally inherited deafness and unusual phenotypic manifestations associated with A3243G mitochondrial DNA mutation.

Authors:  Katalin Komlósi; Richárd Kellermayer; Anita Maász; Viktória Havasi; Katalin Hollódy; Olga Vincze; Hajnalka Merkli; Endre Pál; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

2.  Charles Darwin's mitochondria.

Authors:  John Hayman
Journal:  Genetics       Date:  2013-05       Impact factor: 4.562

3.  Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism.

Authors:  D Meierhofer; J A Mayr; K Fink; N Schmeller; B Kofler; W Sperl
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

4.  MELAS and Kearns-Sayre overlap syndrome due to the mtDNA m. A3243G mutation and large-scale mtDNA deletions.

Authors:  Nian Yu; Yan-Fang Zhang; Kang Zhang; Yuan Xie; Xing-Jian Lin; Qing Di
Journal:  eNeurologicalSci       Date:  2016-04-25

5.  Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) in the 18th Century: Mitochondrial Disorders Are Not of Recent Origin.

Authors:  John Hayman; Steven Pavlakis; Josef Finsterer
Journal:  Cureus       Date:  2022-02-17

6.  Comments on "A Case of MELAS With the m.3243A>G Variant of the MT-TL1 Gene Mimicking Acute Intermittent Porphyria".

Authors:  Josef Finsterer
Journal:  J Clin Neurol       Date:  2022-09       Impact factor: 2.566

7.  Postlingual hearing loss as a mitochondrial 3243A>G mutation phenotype.

Authors:  Katarzyna Iwanicka-Pronicka; Agnieszka Pollak; Agata Skórka; Urszula Lechowicz; Magdalena Pajdowska; Mariusz Furmanek; Maciej Rzeski; Lech Korniszewski; Henryk Skarżyński; Rafał Płoski
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

8.  Mitochondrial multiorgan disorder syndrome score generated from definite mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-06       Impact factor: 2.570

9.  Rare Phenotypic Manifestations of MELAS.

Authors:  Josef Finsterer
Journal:  Yonsei Med J       Date:  2020-10       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.